Search results
Showing 2371 to 2385 of 9043 results
Awaiting development Reference number: GID-TA11623 Expected publication date: TBC
Daratumumab for treating high-risk smouldering multiple myeloma [ID6214]
Awaiting development Reference number: GID-TA11198 Expected publication date: TBC
Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]
Awaiting development Reference number: GID-TA11874 Expected publication date: TBC
Nipocalimab for treating generalised myasthenia gravis [ID6562]
Awaiting development Reference number: GID-TA11492 Expected publication date: TBC
Epilepsies in children, young people and adults (extraordinary review)
In development Reference number: GID-NG10378 Expected publication date: TBC
Awaiting development Reference number: GID-TA11092 Expected publication date: TBC
Awaiting development Reference number: GID-TA11756 Expected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
Awaiting development Reference number: GID-TA11699 Expected publication date: TBC
Awaiting development Reference number: GID-TA11657 Expected publication date: 07 April 2027
Awaiting development Reference number: GID-TA11626 Expected publication date: TBC
Deferred Reference number: GID-TA11531
Awaiting development Reference number: GID-TA11591 Expected publication date: TBC
Awaiting development Reference number: GID-TA11583 Expected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
Awaiting development Reference number: GID-TA11487 Expected publication date: 27 May 2027